An inhibitor of anti-apoptotic Bcl-2 proteins
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

ABT-737

Item No. 11501

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
4-[4-[(4'-chloro[1,1'-biphenyl]-2-yl)methyl]-1-piperazinyl]-N-[[4-[[(1R)-3-(dimethylamino)-1-[(phenylthio)methyl]propyl]amino]-3-nitrophenyl]sulfonyl]-benzamide
CAS Number
852808-04-9
Molecular Formula
C42H45ClN6O5S2
Formula Weight
813.4
Purity
≥98%
Formulation (Request formulation change)
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMF: 10 mg/mlDMF:PBS(pH7.2) (1:2): 0.3 mg/mlDMSO: 5 mg/ml
λmax
251, 311, 409 nm
SMILES
O=C(NS(C1=CC([N+]([O-])=O)=C(N[C@H](CCN(C)C)CSC2=CC=CC=C2)C=C1)(=O)=O)C3=CC=C(N4CCN(CC5=C(C6=CC=C(Cl)C=C6)C=CC=C5)CC4)C=C3
InChi Code
InChI=1S/C42H45ClN6O5S2/c1-46(2)23-22-35(30-55-37-9-4-3-5-10-37)44-40-21-20-38(28-41(40)49(51)52)56(53,54)45-42(50)32-14-18-36(19-15-32)48-26-24-47(25-27-48)29-33-8-6-7-11-39(33)31-12-16-34(43)17-13-31/h3-21,28,35,44H,22-27,29-30H2,1-2H3,(H,45,50)/t3
InChi Key
HPLNQCPCUACXLM-PGUFJCEWSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products
Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $31

    Add

    5 mg

    $84

    Add

    10 mg

    $138

    Add

    25 mg

    $266

    Add
    Cayman Chemical
    Visit Our Cancer Resource Center
    Find Tools & Resources to Study the Hallmarks of Cancer
    • Cancer cell signaling & regulation
    • Cancer metabolism
    • Tumor microenvironment
    EXPLORE NOW
    Product Description

    ABT-737 is a potent, cell-permeable mimetic of BH3 domains that avidly binds Bcl-2, Bcl-xL, and Bcl-W (Ki < 1 nM for all three proteins).1,2 It blocks the interaction of these proteins with pro-death proteins, leading to apoptosis.1 ABT-737, alone, can induce regression of some tumors in some xenograft mouse models of cancer.1,3 It shows synergy with diverse therapeutics and radiation to trigger apoptosis in cancer cells and xenografts.1,4,5

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Oltersdorf, T., Elmore, S.W., Shoemaker, A.R., et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435(7042), 677-681 (2005).

    2. Bruncko, M., Oost, T.K., Belli, B.A., et al. Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL. J. Med. Chem. 50(4), 641-662 (2007).

    3. Ni Chonghaile, T., and Letai, A. Mimicking the BH3 domain to kill cancer cells. Oncogene 27(Suppl 1), S149-S157 (2008).

    4. Trudel, S., Stewart, A.K., Li, Z., et al. The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan. Clin. Cancer Res. 13(2), 621-629 (2007).

    5. Konopleva, M., Watt, J., Contractor, R., et al. Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax). Cancer Res. 68(9), 3413-3420 (2008).

    Product Citations

    Pearson, J.M., Tan, S.-F., Sharma, A., et al. Ceramide analogue SACLAC modulates sphingolipid levels and MCL-1 splicing to induce apoptosis in acute myeloid leukemia. Mol. Cancer Res. 18(3), 352-363 (2020).